Immunic, Inc. IMUX
We take great care to ensure that the data presented and summarized in this overview for IMMUNIC, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IMUX
View all-
Bvf Inc San Francisco, CA8.9MShares$8.72 Million0.33% of portfolio
-
Avidity Partners Management LP Dallas, TX7.97MShares$7.81 Million0.9% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT7.29MShares$7.15 Million0.51% of portfolio
-
Rtw Investments, LP New York, NY4.57MShares$4.48 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.92MShares$3.85 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X02.69MShares$2.64 Million0.0% of portfolio
-
Gratus Capital LLC2.11MShares$2.07 Million0.1% of portfolio
-
Omega Fund Management, LLC Boston, MA1.79MShares$1.75 Million2.73% of portfolio
-
Ikarian Capital, LLC Dallas, TX1.61MShares$1.58 Million0.27% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.4MShares$1.37 Million0.0% of portfolio
Latest Institutional Activity in IMUX
Top Purchases
Top Sells
About IMUX
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Insider Transactions at IMUX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Nov 12
2024
|
Richard Alan Rudick Director |
BUY
Open market or private purchase
|
Direct |
87,300
+50.0%
|
$87,300
$1.15 P/Share
|
|
Feb 26
2024
|
Daniel Vitt CEO and Director |
BUY
Open market or private purchase
|
Indirect |
14,000
+3.46%
|
$14,000
$1.31 P/Share
|
|
May 15
2023
|
Glenn Whaley Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+16.39%
|
$5,000
$1.75 P/Share
|
|
Dec 14
2022
|
Joerg Neermann Director |
BUY
Open market or private purchase
|
Direct |
47,000
+31.97%
|
$47,000
$1.26 P/Share
|
|
Dec 13
2022
|
Joerg Neermann Director |
BUY
Open market or private purchase
|
Direct |
35,000
+39.77%
|
$35,000
$1.25 P/Share
|
|
Nov 23
2022
|
Joerg Neermann Director |
BUY
Open market or private purchase
|
Direct |
18,000
+50.0%
|
$18,000
$1.39 P/Share
|
|
Nov 22
2022
|
Daniel Vitt CEO and Director |
BUY
Open market or private purchase
|
Indirect |
8,000
+2.08%
|
$8,000
$1.35 P/Share
|
|
Nov 07
2022
|
Glenn Whaley Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+19.6%
|
$5,000
$1.5 P/Share
|
|
Jun 03
2022
|
Glenn Whaley Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,500
+21.78%
|
$10,500
$3.04 P/Share
|
|
Jun 03
2022
|
Daniel Vitt CEO and Director |
BUY
Open market or private purchase
|
Indirect |
5,000
+1.34%
|
$15,000
$3.1 P/Share
|
|
May 12
2022
|
Andreas Muehler Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
3,500
+1.16%
|
$17,500
$5.1 P/Share
|
|
May 12
2022
|
Duane Nash Executive Chairman |
SELL
Bona fide gift
|
Direct |
6,000
-27.23%
|
-
|
|
May 12
2022
|
Duane Nash Executive Chairman |
BUY
Open market or private purchase
|
Direct |
10,000
+31.22%
|
$50,000
$5.03 P/Share
|
|
May 12
2022
|
Glenn Whaley Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+24.86%
|
$15,000
$5.08 P/Share
|
|
Aug 10
2021
|
Duane Nash Executive Chairman |
BUY
Open market or private purchase
|
Direct |
1,000
+6.24%
|
$9,000
$9.8 P/Share
|
|
Aug 10
2021
|
Daniel Vitt CEO and Director |
BUY
Open market or private purchase
|
Indirect |
1,000
+0.27%
|
$9,000
$9.6 P/Share
|
|
Aug 10
2021
|
Glenn Whaley Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,500
+30.0%
|
$13,500
$9.85 P/Share
|
|
May 12
2021
|
Duane Nash Executive Chairman |
BUY
Open market or private purchase
|
Direct |
4,000
+22.18%
|
$48,000
$12.75 P/Share
|
|
Mar 02
2021
|
Andreas Muehler Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,006
+3.29%
|
$150,090
$15.54 P/Share
|
|
Mar 02
2021
|
Glenn Whaley Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+33.33%
|
$16,000
$16.48 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 87.3K shares |
|---|